TLR9 and non-small cell lung carcinoma: In fact, preclinical studies on TLR9 agonists demonstrate that these increase antigen-specific T cells in multiple tumour types, including breast cancer, colorectal and non-small-cell lung carcinoma (NSCLC) [60,61,62,63].